 NDA was Submitted in November by TRACONs Corporate Partners, Alphamab Oncology and 3D Medicines, in the Indication of MSI-HdMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in November by TRACONs Corporate Partners, Alphamab Oncology and 3D Medicines, in the Indication of MSI-HdMMR Cancer, Including Colorectal and Gastric Cancer 